Media About Us


  • 18 July 2016

    Pfizer strikes second deal this year for drug production in Russia

    Pfizer strikes second deal this year for drug production in Russia

    Eric Palmer / Fierce Pharma

    Pfizer was a little behind some of its peers in establishing local manufacturing in Russia but it's on a roll now, having just announced its third deal in several years. It is hammering out an agreement with Russia’s NovaMedica for a new manufacturing plant. 

  • 15 July 2016

    Atlas Genetics mandates UBS for up to USD 30m raise Ч source

    Atlas Genetics mandates UBS for up to USD 30m raise Ч source

    Mergermarket

    Atlas Genetics (AG), a UK-based, PE-backed point-of-care (POC) diagnostics company, is looking to raise up to USD 30m to fund clinical trials and commercialization, a source familiar with the situation said. The company has developed ultra-rapid, low cost, multiple analyte detection technology for POC use to screen the presence of sexually transmitted infections (STIs) and hospital acquired infections (HAIs).

  • 15 July 2016

    Pfizer's Russia Deal Shows Country Still Open To Western Business

    Pfizer's Russia Deal Shows Country Still Open To Western Business

    Kenneth Rapoza / Forbes

    U.S. multinational drug maker Pfizer PFE +1.68% is laying down a new foundation in Russia, with a joint venture announced on Wednesday to produce pharmaceuticals domestically.

  • 15 July 2016

    Pfizer links with NovaMedica to produce and market drugs in Russia

    Pfizer links with NovaMedica to produce and market drugs in Russia

    The Pharma Letter

    US pharma giant Pfizer (NYSE: PFE) and NovaMedica, a company established by Russian high-technology investment fund Rusnano and American venture health care fund Domain Associates in 2012, have entered into an agreement to cooperate, signalling the development of a new partnership, to bring important medicines to the Russian market.

  • 13 July 2016

    Photo: Pfizer and NovaMedica announce a strategic partnership in Russia

    Photo: Pfizer and NovaMedica announce a strategic partnership in Russia

    Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have entered into an agreement to cooperate, signalling the development of a new partnership. Through this partnership, Pfizer proposes to invest in NovaMedica’s construction of a new manufacturing plant in the Kaluga region and license the technology for production of more than 30 medicinal products from its portfolio to the Russian partner.

  • 08 July 2016

    EyewireTV Ц FDA Approves Raindrop Inlay; Humira for Uveitis Treatment

    EyewireTV Ц FDA Approves Raindrop Inlay; Humira for Uveitis Treatment

    EyeWire Today

    In this week’s EyewireTV, ReVision Optics receives FDA approval for the Raindrop Near Vision Inlay, the first implantable device that changes the shape of the cornea to achieve improved vision; and the FDA approves Humira (adalimumab) for the treatment of noninfectious intermediate and posterior uveitis and panuveitis. Also, Bausch + Lomb and Nicox announce that the results of a phase 3 study of glaucoma drug candidate latanoprostene bunod have been published in the American Journal of Ophthalmology.

  • 07 July 2016

    Test Aids Prostate Cancer Treatment

    Test Aids Prostate Cancer Treatment

    Ron Winslow / The Wall Street Journal

    Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival. The test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.

  • 30 June 2016

    New blood test from Epic Sciences matches patients with PARP inhibitors

    New blood test from Epic Sciences matches patients with PARP inhibitors

    Josh Baxt / MedCityNews

    San Diego-based liquid biopsy company Epic Sciences has announced a new blood test that may quickly identify cancer patients who respond to a promising class of drugs called poly ADP ribose polymerase (PARP) inhibitors. The test works by identifying circulating tumor cells (CTCs) affected by homologous recombination deficiency (HRD), a damaged DNA repair mechanism.

  • 28 June 2016

    Epic Sciences unveils new, more sensitive biopsy test to detect a range of cancers

    Epic Sciences unveils new, more sensitive biopsy test to detect a range of cancers

    Joseph Keenan / Fierce Medical Devices

    San Diego's Epic Sciences has added a new liquid biopsy test to its arsenal of biopharma cancer detection tools that targets homologous recombination deficiencies (HRDs) in individual circulating tumor cells.

  • 20 June 2016

    BIO-Europe SpringЃ 2016: RMI says it has USD 200 million already under management

    BIO-Europe SpringЃ 2016: RMI says it has USD 200 million already under management

    EBD Group

    Maxim Gorbachev, a partner and portfolio manager at RusnanoMedInvest (RMI) speaks to Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio about Russia’s and Eastern Europe’s largest venture capital company, specializing in innovative developments in the field of pharmaceuticals and biotechnology.